دورية أكاديمية
[Tolerance of bevacizumab therapy in systemic sclerosis-associated pulmonary arterial hypertension: A case report].
| العنوان: | [Tolerance of bevacizumab therapy in systemic sclerosis-associated pulmonary arterial hypertension: A case report]. |
|---|---|
| عنوان ترانسليتريتد: | Tolérance du bévacizumab au cours de l’hypertension artérielle pulmonaire associée à la sclérodermie systémique : à propos d’une observation. |
| المؤلفون: | Sanges S; Université de Lille, 59000 Lille, France; Inserm, U995, 59000 Lille, France; Département de médecine interne et immunologie clinique, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France; Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), 59000 Lille, France; Fédératif hospitalo-universitaire immune-mediated inflammatory diseases and targeted therapies (FHU IMMINeNT), 59000 Lille, France. Electronic address: sebastien_sanges@msn.com., Desauw C; Université de Lille, 59000 Lille, France; Département d'oncologie médicale, CHRU de Lille, 59000 Lille cedex, France., de Groote P; Université de Lille, 59000 Lille, France; Département de cardiologie, CHRU de Lille, 59000 Lille cedex, France., Fertin M; Université de Lille, 59000 Lille, France; Département de cardiologie, CHRU de Lille, 59000 Lille cedex, France., Lamblin N; Université de Lille, 59000 Lille, France; Département de cardiologie, CHRU de Lille, 59000 Lille cedex, France., Bervar JF; Université de Lille, 59000 Lille, France; Département de pneumologie, CHRU de Lille, 59000 Lille cedex, France., Hatron PY; Université de Lille, 59000 Lille, France; Département de médecine interne et immunologie clinique, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France; Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), 59000 Lille, France; Fédératif hospitalo-universitaire immune-mediated inflammatory diseases and targeted therapies (FHU IMMINeNT), 59000 Lille, France., Hachulla E; Université de Lille, 59000 Lille, France; Inserm, U995, 59000 Lille, France; Département de médecine interne et immunologie clinique, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France; Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), 59000 Lille, France; Fédératif hospitalo-universitaire immune-mediated inflammatory diseases and targeted therapies (FHU IMMINeNT), 59000 Lille, France., Launay D; Université de Lille, 59000 Lille, France; Inserm, U995, 59000 Lille, France; Département de médecine interne et immunologie clinique, hôpital Claude-Huriez, CHRU de Lille, rue Michel-Polonovski, 59037 Lille cedex, France; Centre national de référence maladies systémiques et auto-immunes rares (sclérodermie systémique), 59000 Lille, France; Fédératif hospitalo-universitaire immune-mediated inflammatory diseases and targeted therapies (FHU IMMINeNT), 59000 Lille, France. |
| المصدر: | La Revue de medecine interne [Rev Med Interne] 2017 Apr; Vol. 38 (4), pp. 274-277. Date of Electronic Publication: 2016 Jun 28. |
| نوع المنشور: | Case Reports; Journal Article |
| اللغة: | French |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: France NLM ID: 8101383 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3122 (Electronic) Linking ISSN: 02488663 NLM ISO Abbreviation: Rev Med Interne Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Paris : Elsevier Original Publication: Paris : Baillière, [1980- |
| مواضيع طبية MeSH: | Bevacizumab/*therapeutic use , Hypertension, Pulmonary/*drug therapy , Hypertension, Pulmonary/*etiology , Scleroderma, Systemic/*complications , Scleroderma, Systemic/*drug therapy, Aged ; Carcinoma, Squamous Cell/complications ; Carcinoma, Squamous Cell/drug therapy ; Female ; Humans ; Treatment Outcome ; Uterine Neoplasms/complications ; Uterine Neoplasms/drug therapy |
| مستخلص: | Introduction: No data is available regarding the safety of bevacizumab, an anti-vascular endothelial growth factor-A (VEGF-A) antibody, in patients with pulmonary arterial hypertension (PAH), a condition in which VEGF seems to play a significant and probably protective role. Case Report: We report a patient with a history of systemic sclerosis-associated PAH, stable under bosentan therapy. She was diagnosed with metastatic cervical epidermoid carcinoma and treated by two successive cytotoxic chemotherapy regimens. As these treatments failed to control disease progression, she was started on anti-angiogenic therapy: 3 infusions of bevacizumab 15 mg/kg were administered. Over the course of this treatment, no change in the clinical status or echocardiography parameters was noted. Conclusion: This observation suggests that, under careful clinical and echocardiographic follow-up, bevacizumab therapy can be well tolerated in case of stable and moderate PAH. Decision of treatment should be taken cautiously, as the possibility of PAH worsening is not excluded. (Copyright © 2016 Société Nationale Française de Médecine Interne (SNFMI). Published by Elsevier SAS. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Angiogenic inhibitors; Bevacizumab; Bévacizumab; Hypertension artérielle pulmonaire; Inhibiteurs de l’angiogenèse; Pulmonary arterial hypertension; Sclérodermie systémique; Systemic sclerosis; VEGF |
| المشرفين على المادة: | 2S9ZZM9Q9V (Bevacizumab) |
| تواريخ الأحداث: | Date Created: 20160703 Date Completed: 20170928 Latest Revision: 20170928 |
| رمز التحديث: | 20240628 |
| DOI: | 10.1016/j.revmed.2016.05.020 |
| PMID: | 27370897 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1768-3122 |
|---|---|
| DOI: | 10.1016/j.revmed.2016.05.020 |